Abstract

In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• C07K 14/805 - Haemoglobins; Myoglobins
• C12N 5/0775 - Mesenchymal stem cells; Adipose-tissue derived stem cells
• C12N 5/0781 - B cells; Progenitors thereof
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
• C12N 5/0789 - Stem cells; Multipotent progenitor cells
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/864 - Parvoviral vectors

Abstract

Gastrostomy tubes and systems and methods for implanting them are provided. In one example, the gastrostomy tube includes an elongate tubular member including a first end sized for introduction into the patient's mouth, a second end including an expandable member or other bumper, and a feeding lumen extending between the first and second ends. A bolster is connectable around the first end after the first end has been directed from within the patient's stomach through intervening tissue and extends from the patient's skin and the bumper is placed against the wall of the stomach. An adapter is connectable to the bolster after the first end and excess material of the tubular member beyond the bolster has been separated, the adapter including a connector for removably connecting to a feeding tube.

IPC Classes  ?

• A61J 15/00 - Feeding-tubes for therapeutic purposes

Abstract

Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• A61K 35/741 - Probiotics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C12N 1/20 - Bacteria; Culture media therefor
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

Compositions and methods are provided for the identification of peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Abstract

N-Acylated histidine dipeptides of formula N-Acylated histidine dipeptides of formula N-Acylated histidine dipeptides of formula are disclosed. The compounds are useful for treating breast cancer.

IPC Classes  ?

• C07K 5/078 - Dipeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp
• A61P 35/00 - Antineoplastic agents

Abstract

A high-resolution crystallographic structure of the mutant human G267S calpain-5 protease core domain at 2.22 Å resolution is provided. The G267S mutation is associated with hyperactivity of calpain-5 and is linked to the inherited disease, neovascular inflammatory vitreoretinopathy. Methods of using the crystallographic structure in rational design of small molecule drugs that inhibit calpain-5 for treatment of retinal diseases and other diseases associated with calpain-5 hyperactivity are also provided.

IPC Classes  ?

• G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• G16C 20/50 - Molecular design, e.g. of drugs
• G16C 20/64 - Screening of libraries

Abstract

Aspects involve a stretchable composite film including a polymer material having at least a portion of the polymer material being densified through covalently-attached fluorination molecules. In certain specific examples, fluorinated molecules are covalently attached to a surface region, in the form of a layer or film (e.g., polymer semiconductor (PSC) film of a transistor substrate) to facilitate operational stability and/or to encapsulation performance (e.g., stretchability-related performance). In certain other specific examples, the surface region and a fluorinated layer are used in a cooperative configuration to provide stability in the PSC film in one or more harsh environments characterized by one or more of humid air, and immersion of the PSC film in a bio-based fluid.

IPC Classes  ?

• C08F 283/00 - Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass
• H10K 10/46 - Field-effect transistors, e.g. organic thin-film transistors [OTFT]
• H10K 85/10 - Organic polymers or oligomers

Abstract

Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.

IPC Classes  ?

• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/46 - 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• A61K 31/47 - Quinolines; Isoquinolines
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 33/06 - Aluminium, calcium or magnesium; Compounds thereof
• A61K 33/24 - Heavy metals; Compounds thereof
• A61K 33/32 - Manganese; Compounds thereof
• A61K 35/583 - Snakes; Lizards, e.g. chameleons
• A61K 35/64 - Insects, e.g. bees, wasps or fleas
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 38/46 - Hydrolases (3)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 21/06 - Anabolic agents

Abstract

Devices, systems, and methods are provided for relieving peripheral nerve pain in a subject. In one example, the device includes a surface configured for placement against a subject's skin, an imaging element on the housing configured to transmit signals from the surface into the subject's body and receive reflected signals from the body, and one or more transducer elements configured to deliver focused ultrasound from the surface into the body. A controller is coupled to the imaging element to process the reflected signals to identify a target nerve within the body and coupled to the one or more transducer elements to control delivery of the focused ultrasound to the target nerve to relieve pain.

IPC Classes  ?

• A61N 7/02 - Localised ultrasound hyperthermia

Abstract

Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially available materials. The subject methods are scalable with low estimated material costs and can provide enough material to meet clinical needs. Also provided are a variety of bryostatin analog compounds, and prodrug forms thereof, which are synthetically accessible via the subject methods and pharmaceutical compositions including the same.

IPC Classes  ?

• C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 31/365 - Lactones
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61P 35/00 - Antineoplastic agents
• C07D 493/22 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings

Abstract

Methods for identifying biosynthetic gene clusters that include genes for producing compounds that interact with specific target proteins are disclosed. Some methods relate to bioinformatics methods for identifying and/or prioritizing biosynthetic gene clusters. Related systems, components, and tools for the identification and expression of such gene clusters are also disclosed.

IPC Classes  ?

• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G16B 10/00 - ICT specially adapted for evolutionary bioinformatics, e.g. phylogenetic tree construction or analysis
• G16B 25/00 - ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 30/10 - Sequence alignment; Homology search

Abstract

The present disclosure relates to glyconucleic acids, such as glycoRNA and glycoDNA described herein. Provided are glycosylated ribonucleic acid (glycoRNA)-related methods and compositions.

IPC Classes  ?

• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Abstract

Methods of use, pharmaceutical formulations, and labeled versions of compounds are provided of compounds that penetrate the blood-brain barrier and influence the balance of excitatory versus inhibitory neurotransmission by enantiomer selective modulation of glutamate and GABA metabolism. In some embodiments, a glutamatergic false neurotransmitter is S-2-methylglutamate (S-2MeGlu). In some embodiments a GABAergic false neurotransmitters is R-4 aminopentanomic acid (4APA) or S-4 aminopentanomic acid (S-4APA), with high penetration of the blood brain barrier and low toxicity, therein providing useful pharmacologic or imaging agents.

IPC Classes  ?

• A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present disclosure generally relates to engineered Cluster Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated (Cas) 12a proteins and system, and methods for use in gene editing and gene modulation for application to gene therapy. Related systems and methods of gene modulation are also disclosed.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to methods for identifying guide RNAs for use in site-directed RNA editing. In particular, the present invention relates to a high-throughput screening method for identifying guide RNAs effective for site directed A-to-I RNA editing, and methods of use for the identified guide RNAs.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

The present disclosure generally relates to compositions and methods simultaneous, multi-mode gene expression regulation (e.g., simultaneous upregulation and down regulation of multiple target genes). The present disclosure further relates to novel constructs for engineered multiplex CRISPR arrays.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

Methods are provided for the treatment of cancer and/or fibrosis. It is shown that there is increased CD63 expression both in lung cancer and pulmonary fibrosis, sarcoma, skin fibrosis, liver cancer and liver cirrhosis, NASH and NHFLD, and kidney fibrosis from hypertension and other etiologies. Inhibiting CD63 increases phagocytosis of lung cancer cells and lung fibroblasts; and can eliminates tumor cells and pathogenic fibrosis.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 9/22 - Ribonucleases

Abstract

The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 14/72 - Receptors; Cell surface antigens; Cell surface determinants for hormones
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 23/20 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by using reflection of the radiation by the materials
• G01N 33/566 - Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagent

Abstract

The invention generally relates to methods for assessing a neurological disorder by characterizing circulating nucleic acids in a blood sample. According to certain embodiments, methods tor assessing a neurological disorder include obtaining RNA present in a blood sample of a patient suspected of having a neurological disorder, determining a level of RNA present in the sample that is specific to brain tissue, comparing the sample level of RNA to a reference level of RNA specific to brain tissue, determining whether a difference exists between the sample level and the reference level, and indicating a neurological disorder if a difference is determined.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, nucleic acid molecules, such as cell-free nucleic acids, can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and/or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.

IPC Classes  ?

• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 25/00 - ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
• G16B 25/20 - Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 30/10 - Sequence alignment; Homology search
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Compositions comprising an iboga alkaloid and a cardioprotective agent are provided. Use of the compositions in treating neuropsychiatric disorders are described, where the cardioprotective agent is administered before, during and/or after the iboga alkaloid.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 33/06 - Aluminium, calcium or magnesium; Compounds thereof
• A61P 9/06 - Antiarrhythmics
• A61P 25/24 - Antidepressants

Abstract

Methods for treating a neuropsychiatric disorder by administering an iboga alkaloid and a cardioprotective agent in conjunction with analysis of brain image data is described. Also described are methods to improve brain health and to slow or reverse brain aging by disorder by administering an iboga alkaloid and a cardioprotective agent, where analysis of brain image data is used to monitor and/or evaluate treatment effectiveness.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 33/06 - Aluminium, calcium or magnesium; Compounds thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present disclosure provides methods of improving the structure and/or function of a joint tissue of a subject by administering to the subject an amount of a 15-PGDH inhibitor effective to inhibit 15-PGDH activity and/or reduce 15-PGDH levels in the subject. The methods described herein are useful for treating joint dysfunction and/or degeneration associated with aging, injury, disease, disorder, and/or condition.

IPC Classes  ?

• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

Inducible promoters for the coordinated expression of at least one heterologous gene in yeast and methods of using them are disclosed. In particular, the invention relates to sets of inducible promoters derived from S. cerevisiae and related species that can be induced in the presence of nonfermentable carbon sources.

IPC Classes  ?

• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Abstract

Provided herein are, inter alia, methods for treating subjects in need of an IL-1 inhibitor therapy or an IL-6 inhibitor therapy, and related methods. The methods include determining whether the subject is at risk for drug-related hypersensitivity by assaying for the presence of certain HLA alleles.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present disclosure relates to methods of inhibiting reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in a subject. In one embodiment, the method involves administering an inhibitor of Elongation of Very Long Chain Fatty Acids Protein 1 (ELOVL1) to a subject having or at risk of having a condition mediated by reactive astrocytes, where the ELOVL1 inhibitor is administered in an amount effective to inhibit reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in the subject. In another embodiment, the method involves administering an inhibitor of lipoapoptosis to a subject having or at risk of having a condition mediated by reactive astrocytes, where the inhibitor of lipoapoptosis is administered in an amount effective to inhibit reactive astrocyte mediate neuronal and/or oligodendrocyte cell death in the subject.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Compositions and methods are provided for the reversible modification of RNA to enhance RNA in-solution and enzymatic stability by reaction with acylimidazoles, sulfonyltriazoles, or sulfonylimidazoles. 2′-OH acylation protects RNA from hydrolytic and enzymatic degradation. Water-soluble organocatalysts can accelerate the reversal of acylation adducts and functionally restore RNAs, alternatively the acylation is spontaneously reversed in a cellular environment. Chemically tuned 2′-OH acylation can be spontaneously released in cells to restore RNA biological functions including translation. mRNA can be selectively modified at the 2′-OH of poly(A)-tail for enhanced in-cell stability and enhanced total protein output.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Abstract

Engineered proteins, polynucleotides encoding such proteins, and methods of use thereof are provided, which engineered proteins enhance the sensitivity of a cell to IL-2.

IPC Classes  ?

• C07K 14/55 - IL-2
• C07K 14/715 - Receptors; Cell surface antigens; Cell surface determinants for interferons

Abstract

Blockchain-based, smart contract platforms have great promise to remove trust and add transparency to distributed applications. However, this benefit often comes at the cost of greatly reduced privacy. Techniques for implementing a privacy-preserving smart contract is described. The system can keep accounts private while not losing functionality and with only a limited performance overhead. This is achieved by building a confidential and anonymous token on top of a cryptocurrency. Multiple complex applications can also be built using the smart contract system.

IPC Classes  ?

• G06Q 20/38 - Payment architectures, schemes or protocols - Details thereof
• G06Q 20/06 - Private payment circuits, e.g. involving electronic currency used only among participants of a common payment scheme
• G06Q 20/36 - Payment architectures, schemes or protocols characterised by the use of specific devices using electronic wallets or electronic money safes
• H04L 9/00 - Arrangements for secret or secure communications; Network security protocols
• H04L 9/06 - Arrangements for secret or secure communications; Network security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems
• H04L 9/32 - Arrangements for secret or secure communications; Network security protocols including means for verifying the identity or authority of a user of the system

Abstract

The present disclosure provides methods and compositions for treating SCID-X1 in subjects, comprising genetically modifying cells from the subjects ex vivo by integrating a full-length, codon-optimized IL2RG cDNA at the endogenous IL2RG locus.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C12N 5/0789 - Stem cells; Multipotent progenitor cells
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

In certain examples, methods and apparatuses, such as circuits, are directed to scanning in a field of view (FoV) by using a pattern that improves sensing in a region of interest (RoI) within the FoV. In one example, a signal having multiple frequency components and a scan-pattern design are used, with a balanced or optimized set of attributes including a sampling density attribute, to scan a RoI in a FoV by sampling or traversing the RoI more times than other regions in the FoV. In more specific examples, circuitry finds the scan-pattern design based on an algorithm that processes different parameters involving at least one of amplitude and phase and processes a. number of different frequency components related to or including the multiple frequency components, wherein the number of different frequency components is from three to a threshold limit whereat processing different frequency components provides negligible improvement.

IPC Classes  ?

• G01S 17/89 - Lidar systems, specially adapted for specific applications for mapping or imaging
• B81B 7/02 - Microstructural systems containing distinct electrical or optical devices of particular relevance for their function, e.g. microelectro-mechanical systems (MEMS)
• G01S 7/481 - Constructional features, e.g. arrangements of optical elements

Abstract

Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Provided are recombinant polypeptides that comprise a protein of interest, a protein localization tag, and a protease cleavage site disposed between the protein of interest and the protein localization tag. In certain embodiments, the recombinant polypeptides further comprise a protease, where the protease cleavage site is a cleavage site for the protease. Also provided are nucleic acids that encode the recombinant polypeptides, cells that comprise such nucleic acids, and compositions (e.g., pharmaceutical compositions) that comprise such cells. Methods of regulating cellular localization of a protein of interest, and methods of administering a regulatable cell-based therapy to an individual in need thereof, are also provided.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

Abstract

Systems and methods are provided for altering the shape of a target tissue structure of a subject, e.g., a nasal septum or other nasal tissue that include securing a first end of a shaping element to tissue adjacent the structure; manipulating the tissue to alter a shape of the structure; and applying a force to the shaping element to maintain the altered shape of the structure.

IPC Classes  ?

• A61F 2/18 - Internal ear or nose parts, e.g. ear-drums
• A61F 2/28 - Bones

Abstract

Systems and methods for neuronavigation in accordance with embodiments of the invention are illustrated. Targeting systems and methods as described herein can generate personalized stimulation targets for the treatment of mental conditions. In many embodiments, direct stimulation of a personalized the stimulation target indirectly impacts a brain structure that is more difficult to reach via the stimulation modality. In various embodiments, the mental condition is major depressive disorder. In a number of embodiments, the mental condition is suicidal ideation.

IPC Classes  ?

• A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61N 1/20 - Applying electric currents by contact electrodes continuous direct currents
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 2/00 - Magnetotherapy
• G01R 33/48 - NMR imaging systems
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques

Abstract

A method is provided. The method includes determining an open circuit voltage of a battery of a vehicle. The method also includes determining a voltage of a current provided to the battery of the vehicle. The method further includes determining a impedance indicator based on the voltage, the open circuit voltage, and the current provided to the battery of the vehicle. The method further includes determining a health of the battery based on the impedance indicator.

IPC Classes  ?

• G01R 31/392 - Determining battery ageing or deterioration, e.g. state of health
• G01R 31/3842 - Arrangements for monitoring battery or accumulator variables, e.g. SoC combining voltage and current measurements
• G01R 31/389 - Measuring internal impedance, internal conductance or related variables

Abstract

Methods are provided herein for modulating the epigenome of immune cells by administration of an immunostimulatory composition comprising adjuvants, e.g. vaccine adjuvants, to stimulate broad and persistent innate immunity against pathogens unrelated to antigens present in the composition.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/12 - Viral antigens
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof

Abstract

Methods and compositions are provided for the treatment of glaucoma and other optic neuropathies.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/46 - Hybrid immunoglobulins
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure provides systems, compositions and methods for regulating expression of a target polynucleotide in a cell. The systems, compositions and methods comprise a chimeric receptor polypeptide comprising a G-protein coupled receptor (GPCR) or a fragment thereof, a chimeric adaptor polypeptide, at least one actuator moiety and a cleavage moiety.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C12N 9/22 - Ribonucleases

Abstract

Systems and methods for generating knowledge graphs and text summaries from document databases are provided. In one embodiment, a system for generating knowledge graphs and text summaries includes: a device, including: a processor; and a memory containing a knowledge graph and text summary generating application, where the knowledge graph and text summary generating application directs the processor to: query a global network of biomedical relationships; construct a knowledge graph and a citation graph; apply processes to learn local context-based weights and compute summarizations; and provide results via a display.

IPC Classes  ?

• G06F 16/34 - Browsing; Visualisation therefor
• G06F 16/36 - Creation of semantic tools, e.g. ontology or thesauri

Abstract

De novo designed polypeptides that bind to IL-2 receptor βγc heterodimer (IL-2Rβγc), IL-4 receptor αγc heterodimer (IL-4Rαγc), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.

IPC Classes  ?

• C07K 14/55 - IL-2
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• C07K 14/54 - Interleukins (IL)

Abstract

The present invention relates to a method for selectively transducing retinal and optic nerve head (ONH) astrocytes using adeno-associated virus serotype 5 (AAV5) in combination with a modified glial fibrillary acidic protein promoter (gfaABC1D) for delivery of gene therapies (recombinant DNA, shRNA, Crispr/Cas9) to treat glaucoma or other optic neuropathies

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 27/02 - Ophthalmic agents
• C12N 9/22 - Ribonucleases
• C12N 15/86 - Viral vectors

Abstract

Methods for labeling and imaging the accessible genome using a transposase are disclosed. In some embodiments, a bifunctional transposase complex or transposome is used to insert adaptors comprising chemical tags selectively at accessible sites in the genome where active regulatory DNA is located. Various chemical tags can be used for labeling DNA at insertion sites, including, for example, fluorescent dyes for fluorescence imaging, metal particles for electron microscopy or magnetic manipulation of DNA, isotopic labels, or biotin or other ligands, haptens, substrates, or inhibitors that are recognized by streptavidin, antibodies, enzymes, or receptors. Labeling DNA in this manner can be used to provide spatial information regarding the positioning of regulatory DNA in the genome and makes possible the imaging and sorting of cells based on the status of their regulatory DNA.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C07K 1/13 - Labelling of peptides
• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

Compounds useful as contrast agents in image-guided surgery are provided. The compounds comprise a latent cationic lysosomotropic fragment that is detectable upon cleavage by lysosomal proteases within treated tissues, particularly within tumors and other diseased tissues. Also provided are compositions comprising the compounds and methods for using the compounds, for example in dynamically monitoring protease activity in vivo during image-guided tumor resection surgery.

IPC Classes  ?

• G01N 33/532 - Production of labelled immunochemicals
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07K 5/065 - Dipeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
• C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Abstract

Methods of differentiating pluripotent stem cells into thymic epithelial progenitor cells are provided.

IPC Classes  ?

• C12N 5/078 - Cells from blood or from the immune system

Abstract

An antigen-specific T cell binding agent is provided, where a multivalent ‘spheromer’ system utilizes a scaffold of a self-assembling polypeptide nanoparticle, for example using selfassembling ferritin polypeptides. The system is compatible with current pMHC reagents, including both MHC-I and MHC-II molecules, and streptavidin reagents that allow ease-of-use. The spheromer assembly pipeline provides a consistent reagent across multiple batches of synthesis with ease of production. The defined geometry of the scaffold allows precise site-directed conjugation of pMHC, leading to a homogenous reagent. The spheromer binds cognate TCRs with a significantly higher avidity than a tetrameric reagent.

IPC Classes  ?

• C07K 14/79 - Transferrins, e.g. lactoferrins, ovotransferrins
• C07K 14/74 - Major histocompatibility complex (MHC)
• C12N 9/10 - Transferases (2.)
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Miscible antifoams are provided that do not separate out of a target liquid and that are easy to incorporate in the target liquid. A method or system involves mixing a liquid (‘a miscible antifoam’) into a target foaming liquid. This miscible antifoam is engineered/chosen such that it has both a higher surface tension and is more volatile than the target liquid, or engineered such that it has both a lower surface tension and is less volatility than the target liquid. The miscible antifoam leads to surface tension gradients that cause bubble rupture up to 10 times faster than the target liquid without the antifoam. Further, the miscible antifoams are easy to incorporate and do not separate out from the target liquid during operation—both of which are key limitations faced by existing antifoams.

IPC Classes  ?

• C10M 169/00 - Lubricating compositions characterised by containing as components a mixture of at least two types of ingredient selected from base-materials, thickeners or additives, covered by the preceding groups, each of these compounds being essential
• B01D 19/04 - Foam dispersion or prevention by addition of chemical substances
• C10L 1/08 - Liquid carbonaceous fuels essentially based on blends of hydrocarbons for compression ignition
• C10M 127/06 - Alkylated aromatic hydrocarbons

Abstract

Injection of silicon oil (SO) to the anterior chamber of an eye efficiently induces intraocular pressure (TOP) elevation. This effect occurs without causing overt ocular structural damage or inflammatory responses while simulating acute glaucomatous changes that human patients develop over years by inducing progressive RGC and ON degeneration and visual functional deficits within weeks. The anterior segments of the experimental eyes are not substantially affected, leaving clear ocular elements that allow easy and reliable assessment of in vivo visual function and morphology. More importantly, this is the only reversible ocular hypertension model by removing SO from the anterior chamber and particularly useful for testing neuroprotection treatment together with lowering TOP treatment. In summary, the acute ocular hypertension glaucoma model replicates secondary post-operative glaucoma. It is straightforward and reversible, does not require special equipment or repeat injections, and may be applicable to a range of animal species with only minor modifications.

IPC Classes  ?

• A61F 9/007 - Methods or devices for eye surgery
• G09B 23/30 - Anatomical models

Abstract

Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• A61K 35/741 - Probiotics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C12N 1/20 - Bacteria; Culture media therefor
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

The present disclosure provides compositions comprising chemerin and the methods of use thereof. The compositions of the disclosure are useful in the treatment of cancer.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C07K 14/52 - Cytokines; Lymphokines; Interferons

Abstract

Improved resolution of a time-varying optical measurement is provided with optical intensity modulator(s) having a bandwidth greater than that of the detector array(s). The modulator configuration can have high photon collection efficiency, e.g. by using polarization modulation to split the incident light into several time-gated channels.

IPC Classes  ?

• G01J 3/44 - Raman spectrometry; Scattering spectrometry
• G01J 3/28 - Investigating the spectrum
• G01N 21/64 - Fluorescence; Phosphorescence

Abstract

Compositions and methods are provided for the identification of peptide sequences that are presented to T cells in an MHC context.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• H01J 49/00 - Particle spectrometers or separator tubes
• H01J 49/16 - Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission

Abstract

Devices and methods for treating obstructive sleep apnea, habitual mouth breathing, and/or myofunctional therapy includes a body including an anterior end, a posterior end, and lateral portions shaped for introduction into a subject's oral cavity to position the anterior end adjacent front teeth of the subject and the posterior end adjacent the pharyngeal airway of the subject with or without the posterior end adjacent the pharyngeal airway. Sensors and/or stimulators may be provided, to generate electrical current, chemical release, vibration, and/or other stimulations, e.g., to activate neuromuscular contraction, stimulate salivation and subsequent swallowing movement, and/or induce partial wakefulness of the subject and/or to record data regarding the subject's tongue movements and/or position. Optionally, an extraoral sensor device may be provided for placement around the face, nose, check, abdomen, or neck, which may be paired with the intraoral device to detect the respiratory effort related airway obstruction.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The invention described herein relates to a prodrug that is converted into a dopamine agonist. The dopamine prodrug may be combined with one or more dopamine antagonists, dopamine receptor inhibitors, or vesicular monoamine transport inhibitors. A prodrug is a biologically inactive compound that can be metabolized by the body into its active form. For example, a prodrug placed on the ocular surface can undergo hydrolysis during penetration of the ocular surface, resulting in a biologically active drug. A prodrug allows for use of a lower concentration of the drug and protects against undesirable side effects. A prodrug can also help augment drug uptake into the target tissue.

IPC Classes  ?

• A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

A method of identifying methylated cell-free DNA (cfDNA) biomarkers is provided, referred to as layered analysis of methylated biomarkers (LAMB). In particular, the LAMB methodology can be used to analyze data from patients to discover methylated cfDNA biomarkers associated with cancer. LAMB was used to identify tumor suppressor candidates using meta-analysis of cancer tissue methylation studies, followed by screening for tumor-specific promoter CpGs in these tumor suppressors and analysis of microarray data for cancerous tissues, non-cancerous tissues adjacent to tumors, and healthy blood samples. Biomarker panels for diagnosis of liver, colorectal, prostate, and lung cancer as well as biomarkers for predicting tumor response to therapy are provided based on this LAMB methodology. The biomarkers identified by LAMB can be used alone or in combination with one or more additional biomarkers or relevant clinical parameters in prognosis, diagnosis, therapy selection, or monitoring treatment of cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Compositions and methods are provided for the analysis and treatment of conditions relating to clonal hematopoiesis of indeterminate potential (CHIP). In some embodiments, treatment is provided to reduce the progression of CHIP, particularly to reduce the progression to hematologic malignancy and/or heart disease. In other embodiments, methods are provided for determining clonal expansion, for example as a molecular diagnostic test that enables determination of clonal growth rate from a single sample. The method for determining clonal expansion can be applied to identify factors that influence clonal expansion, including environmental, metabolic, microbiome, and genetic.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 38/46 - Hydrolases (3)
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Devices and methods are provided for supporting a subject's heart, e.g., to support the left and/or right ventricles of the heart, e.g., to prevent and/or treat heart failure. In one example, the device includes a sleeve configured to be implanted over a region of the subject's heart including a lattice formed on a surface of the sleeve. The sleeve may be positioned and permanently implanted over a desired region of the subject's heart to provide passive support to ventricular tissue of the heart.

IPC Classes  ?

• A61F 2/24 - Heart valves

Abstract

A polyacrylamide-based copolymer reduces or prevents aggregation of biologic molecules including proteins, peptides, and nucleic acids, and lipid-based vehicles such as liposomes, lipid nanoparticles, polymerosomes, and micelles, in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of the molecules in the formulation. Methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used for treating conditions including diabetes.

IPC Classes  ?

• C08F 220/36 - Esters containing nitrogen containing oxygen in addition to the carboxy oxygen
• A61K 9/127 - Liposomes
• A61K 9/51 - Nanocapsules

Abstract

Systems and methods for predicting and treating relapses for neurological conditions in accordance with embodiments of the invention are illustrated. One embodiment includes a method for predicting and treating a clinical neurological condition relapse. The method includes steps for selecting a threshold heart rate variability value for a patient suffering from a clinical neurological condition, monitoring, using a cardiac monitor, the heart rate variability of the patient over time, providing an indicator that a relapse is imminent when the heart rate variability of the patient falls below the threshold heart rate variability value, and treating the patient using a transcranial magnetic stimulation device by applying an accelerated theta burst stimulation protocol where the transcranial magnetic stimulation target is the left prefrontal dorsolateral cortex.

IPC Classes  ?

• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/16 - Devices for psychotechnics; Testing reaction times
• A61N 2/00 - Magnetotherapy
• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
• G01R 33/48 - NMR imaging systems
• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising

Abstract

A group of state-action history entries may be determined from state-action history entries stored in a database. A state-action history entry may represent an experienced operational scenario. A state-action history entry may be associated with a feature. The group of state-action history entries may be determined based on a similarity of the feature. A parameter may be generated based on the group of state-action history entries. The parameter may represent a probability associated with experienced operational scenarios that are similar to one another. A model may be generated based on the parameter. The model may be configured for use in an operational scenario that is similar to the experienced operational scenarios when traversing a portion of the vehicle transportation network.

IPC Classes  ?

• B60W 50/06 - Improving the dynamic response of the control system, e.g. improving the speed of regulation or avoiding hunting or overshoot
• B60W 60/00 - Drive control systems specially adapted for autonomous road vehicles
• G06N 7/00 - Computing arrangements based on specific mathematical models
• G06N 20/00 - Machine learning

Abstract

Systems and methods for path planning with latent state inference and spatial-temporal relationships are provided. A system includes an inference module, a policy module, a graphical representation module, and a planning module. The inference module receives sensor data associated with a plurality of agents. The inference module also maps the sensor data to a latent state distribution to identify latent states of the plurality of agents. The latent states identify agents of the plurality of agents as cooperative or aggressive. The policy module predicts future trajectories of the plurality of agents at a given time based on sensor data and the latent states of the plurality of agents. The graphical representation module generates a graphical representation based on the sensor data and a graphical representation neural network. The planning module generates a motion plan for the ego agent based on the predicted future trajectories and the graphical representation.

IPC Classes  ?

• G05D 1/02 - Control of position or course in two dimensions
• B60W 40/04 - Traffic conditions
• G06N 3/08 - Learning methods

Abstract

Photovoltaic retinal prosthesis is provided with optically configurable confinement of electrical field. A video stream is projected onto a retinal implant. An array of photovoltaic pixels is configured to provide retinal stimulus responsive to the video stream. The photovoltaic pixels have a common return electrode. Each pixel has an active electrode that is coupled to retinal tissue via a capacitive interface or a faradaic interface. Each pixel includes photodiode(s) connected in series between the common return electrode and the corresponding active electrode. The projected video stream is configured based on a source video stream such that one or more pixels of the retinal implant that will be dark in a next frame of the projected video stream are optically preconditioned (pre-charged) by the projected video stream during the previous frame to become sufficiently conductive to act as transient local return electrodes during the next frame of the projected video stream.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

Abstract

Therapeutic and diagnostic methods are provided, which methods relate to the induction of expression of calreticulin on phagocytic cells. Specifically, the methods relate to macrophage-mediated programmed cell removal (PrCR), the methods comprising increasing PrCR by contacting a phagocytic cell with a toll-like receptor (TLR) agonist; or down-regulating PrCR by contacting a phagocytic cell with an inhibitor of Bruton's tyrosine kinase (BTK). In some embodiments, an activator of TLR signaling or a BTK agonist is provided in combination with CD4 7 blockade.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
• A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12N 5/0786 - Monocytes; Macrophages

Abstract

The present disclosure provides methods for treating a disease or disorder or sensitizing a cell to phagocytosis. The methods comprise contacting a cell with an inhibitor of Adipocyte Plasma Membrane Associated Protein (APMAP), an agonist of fatty-acid G-protein coupled receptor GPR84, or a combination thereof. The methods may further comprise contacting the cell with at least one or both of a tumor antigen (TA)-targeting antibody and a CD47 blocking antibody. The present disclosure also provides methods for determining cellular regulators of phagocytosis.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12N 5/078 - Cells from blood or from the immune system
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are methods of analyzing a capillary microsample obtained from a subject. In certain embodiments, the methods comprise assessing a test mixture for one or more capillary microsample analytes, wherein the test mixture comprises the capillary microsample diluted into a stabilizing buffer comprising isopropanol, ethanol, methanol, or a combination thereof. Such methods further comprise analyzing capillary microsample nucleic acids purified from the test mixture. According to some embodiments, analyzing the capillary microsample nucleic acids comprises genotyping the subject. Methods of determining one or more alleles of a subject are also provided, as are kits that find use in practicing the methods of the present disclosure.

IPC Classes  ?

• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6858 - Allele-specific amplification

Abstract

A hybrid analog-digital electronic circuit for solving non-linear programming problems includes an analog circuit and a digital microcontroller interconnected to each other by an analog-to-digital converter (ADC) and a digital-to-analog converter (DAC). The analog circuit physically realizes a nonlinear programming problem (NLP) where voltages in the analog circuit represent variables in the NLP, and the interconnection of the analog circuit components enforce Karush-Kuhn-Tucke r (KKT) conditions on the variables, such that the voltages in the analog circuit that represent the variables of the NLP naturally converge to an optimal and feasible solution of the NLP. The digital microcontroller sets the voltages in the analog circuit at particular nodes in the analog circuit through the DAC, where the voltages set at the particular nodes determine a precise cost function to be minimized by the analog circuit, where the voltages set at the particular nodes are computed by the digital microcontroller based on measurements obtained from the analog circuit through the ADC.

IPC Classes  ?

• H03M 1/06 - Continuously compensating for, or preventing, undesired influence of physical parameters

Abstract

Disclosed are methods of treating an ocular disease associated with retinal ischemic injury in a subject comprising administering to the subject a p75NTR modulator, a MSC comprising decreased p75NTR expression or activity or a MSC secretome collected from a MSC comprising decreased p75NTR expression or activity. Disclosed are methods of treating late stage diabetes in a subject comprising administering to the subject in need thereof a p75NTR modulator, a MSC comprising decreased p75NTR expression or activity or a MSC secretome collected from a MSC comprising decreased p75NTR expression or activity.

IPC Classes  ?

• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61P 27/02 - Ophthalmic agents
• A61K 38/18 - Growth factors; Growth regulators
• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.

IPC Classes  ?

• A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/26 - Glucagons
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

Compositions and methods are provided for stratification of ductal carcinoma in situ (DCIS) tumors with respect to prognostic features that distinguish primary DCIS tumors with a high probability of recurrence and invasive disease, representing tumor progression, from tumors that will not recur. Stratification methods may comprise analysis of a DCIS tissue sample with MIBI-TOF imaging.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• H01J 49/00 - Particle spectrometers or separator tubes

Abstract

Embodiments of the synthesis, radiolabeling and biological applications of an activatable tracer that undergoes intramolecular cyclization and aggregation upon activation by cleavage of a blocking moiety are provided. The probes of the disclosure allow for target-controlled self-assembly of small molecules in living subjects for imaging and drug delivery. The aggregated nanoprobes of the disclosure may be detectable optically, by PET detection, magnetic resonance imaging, and the like depending on the detectable reporter attached to the nanoprobe.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins
• C07K 5/113 - Tetrapeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
• C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala

Abstract

Implantable devices and/or sensors can be wirelessly powered by controlling and propagating electromagnetic waves in a patient's tissue. Such implantable devices/sensors can be implanted at target locations in a patient, to stimulate areas such as the heart, brain, spinal cord, or muscle tissue, and/or to sense biological, physiological, chemical attributes of the blood, tissue, and other patient parameters. The propagating electromagnetic waves can be generated with sub-wavelength structures configured to manipulate evanescent fields outside of tissue to generate the propagating waves inside the tissue. Methods of use are also described.

IPC Classes  ?

• A61N 1/378 - Electrical supply
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/372 - Arrangements in connection with the implantation of stimulators
• H02J 50/10 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling
• H02J 50/20 - Circuit arrangements or systems for wireless supply or distribution of electric power using microwaves or radio frequency waves
• A61N 1/362 - Heart stimulators
• A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
• H02J 50/00 - Circuit arrangements or systems for wireless supply or distribution of electric power
• H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/365 - Heart stimulators controlled by a physiological parameter, e.g. by heart potential
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/01 - Measuring temperature of body parts
• A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body
• A61B 5/026 - Measuring blood flow
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• A61H 23/00 - Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61N 1/375 - Constructional arrangements, e.g. casings
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• A61N 5/06 - Radiation therapy using light
• A61N 7/00 - Ultrasound therapy
• A61H 1/00 - Apparatus for passive exercising; Vibrating apparatus; Chiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones 

Abstract

Systems, methods, and kits for enhancing mRNA translation are disclosed. Some embodiments describe expression constructs for producing a peptide and include a translational enhancer. Additional embodiments describe methods for producing a peptide using a construct including a translational enhancer. Certain embodiments further enhance mRNA stability.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

The present invention provides, inter alia, methods, apparatus, and systems useful for ameliorating impulse control disorders known to be extremely disabling and common to many neurological and psychiatric conditions using closed-loop (responsive) neuro stimulation.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

Electrochemical reactivity is driven by the composition and structure of electrode surfaces. Monitoring surface chemistry in operando is thus crucial to understanding the behavior of electrodes yet is often inaccessible either due to resource limitations or to technical challenges in replicating realistic reaction environments. The invention presents a color impedance spectroscopy (CIS)-based technique to access operando surface measurements for mixed ionic-electronic conductors (MIECs). The CIS technique tunes the depth of charge carriers' movement within an electrode material by modulating the frequency of an applied AC electrochemical signal and monitors these changes spectroscopically. The results enable surface sensitivity in conventional bulk spectroscopies and provide new opportunities to characterize the operational behavior of MIEC electrodes.

IPC Classes  ?

• G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
• G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance

Abstract

Ultrasound imaging and therapy with the same array of capacitive micromachined ultrasonic transducers is provided. The electronics includes a per-pixel switch for each transducer element. The switches provide an imaging mode driven completely by on-chip electronics and a therapy mode where off-chip pulsers provide relatively high voltages to the transducer elements.

IPC Classes  ?

• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61N 7/00 - Ultrasound therapy
• B06B 1/02 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy
• A61N 7/02 - Localised ultrasound hyperthermia

Abstract

Disclosed herein are compositions and methods for sequencing, analyzing, and utilizing samples such as single samples. Also disclosed herein are compositions and methods for matching together two or more sequences from a sample. Also disclosed herein are compositions and methods for expressing and screening molecules of interest.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

An implantable device is provided that can include any number of features. In some embodiments, the device includes a coil antenna configured to receive wireless power from a power source external to the patient. The device can include at least one sensor configured to sense a bodily parameter of the patient. The device can also include electronics configured to communicate the sensed bodily parameter of to a device located external to the patient. Methods of use are also described.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/03 - Measuring fluid pressure within the body other than blood pressure, e.g. cerebral pressure
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 5/06 - Radiation therapy using light
• A61N 7/00 - Ultrasound therapy
• A61N 2/00 - Magnetotherapy
• A61B 5/07 - Endoradiosondes
• H01L 23/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details of semiconductor or other solid state devices
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof

Abstract

Underwater adhesive are provided that include a hydrophobic polymer backbone having periodically embedded dynamic bonding units, where the underwater adhesive has nanophase separation between a first phase of the hydrophobic polymer backbone and a second phase of the dynamic bonding units. The resulting nanophase-separated morphology has clusters of dynamically bonded groups that are protected from water by a surrounding matrix of hydrophobic polymer backbone. This enables a pressure sensitive underwater adhesive with advantages of: no curing needed, reusable, recyclable, and good adhesion strength.

IPC Classes  ?

• C09J 7/38 - Pressure-sensitive adhesives [PSA]

Abstract

Methods and compositions are provided for the treatment of cancer with a targeted therapy in combination with radiation. Administration of an effective dose or series of doses of a CD47 blocking agent, i.e. an agent that blocks the interaction between CD47 and SIRPα, is combined with radiation therapy to provide for an abscopal effect. In some embodiments the cancer is a metastatic cancer, or a cancer with a high likelihood of metastasis.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

Preclinical cancer research is heavily dependent on allograft and xenograft models, but current approaches to tumor inoculation yield inconsistent tumor formation and growth, ultimately wasting valuable resources (e.g., animals, time, and money) and limiting experimental progress. A method and kit for tumor inoculation is disclosed using self-assembled hydrogels to reliably generate tumors with low variance in growth. The observed reduction in model variance enables smaller animal cohorts, improved effect observation and higher-powered studies.

IPC Classes  ?

• A01K 67/027 - New breeds of vertebrates
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/38 - Animal cells

Abstract

A variable impedance actuator is provided with a bladder-style actuator having a first end and a second end, and a jamming brake located inside the bladder-style actuator and connected to the first end and the second end of the bladder-style actuator. The bladder-style actuator and the jamming brake are independently controlled.

IPC Classes  ?

• F15B 15/10 - Fluid-actuated devices for displacing a member from one position to another; Gearing associated therewith characterised by the construction of the motor unit the motor being of diaphragm type
• B25J 19/00 - Accessories fitted to manipulators, e.g. for monitoring, for viewing; Safety devices combined with or specially adapted for use in connection with manipulators
• B25J 9/14 - Programme-controlled manipulators characterised by positioning means for manipulator elements fluid

Abstract

A fully 3-D printed, soft, monolithic 4-DoF fingertip haptic technology is provided, called FingerPrint, that stimulates linear and rotational shear, pressure, and vibration on the finger pad. Constructed using an origami waterbomb base mechanism and printed from a flexible material, the device embeds four sets of eight foldable vacuum-powered pneumatic actuators to achieve three translational (x, y, z) and one rotational (torsion) tactile motions and forces of a tactor end-effector on the finger pad skin.

IPC Classes  ?

• G08B 6/00 - Tactile signalling systems, e.g. personal calling systems
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• B33Y 80/00 - Products made by additive manufacturing

Abstract

Processes and materials to detect cancer from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences derived from a neoplasm. Detection of somatic variants occurring in phase can indicate the presence of cancer in a diagnostic scan and a clinical intervention can be performed.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 30/10 - Sequence alignment; Homology search
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 35/20 - Screening of libraries
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
• G16H 70/60 - ICT specially adapted for the handling or processing of medical references relating to pathologies
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G16B 20/10 - Ploidy or copy number detection
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• C12Q 1/6869 - Methods for sequencing
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Abstract

Compositions and methods are provided for the achievement of organ and tissue transplantation and autoimmune tolerance using the infusion of living and/or deceased donor hematopoietic cells. The methods provided herein provide for conditioning with a plurality of doses of total lymphoid irradiation (TLI), and a single, very low dose of TBI (svldTBI), referred to herein as “TLI-svldTBI-ATG” or “TLI-svldTBI” depending on whether ATG is included. The combination of svldTBI and TLI specifically targets non-lymphoid-tissue resident memory immune cells. An in vitro manipulated donor cell composition is provided for use with the conditioning regimen, in which specific ratios of CD34+ and other hematopoietic stem cell and precursor cell populations are combined with defined doses of CD3+ T cells, and/or purified regulatory T cells (Treg) cells, invariant natural killer (iNK-T) cells, and/or CD8+ memory T cells.

IPC Classes  ?

• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Compounds useful as contrast agents in image-guided surgery are provided. The compounds comprise a latent cationic lysosomotropic fragment that is detectable upon cleavage by lysosomal proteases within treated tissues, particularly within tumors and other diseased tissues. Also provided are compositions comprising the compounds and methods for using the compounds, for example in dynamically monitoring protease activity in vivo during image-guided tumor resection surgery.

IPC Classes  ?

• C07K 5/068 - Dipeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
• A61K 49/00 - Preparations for testing in vivo
• C07D 403/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 51/08 - Peptides, e.g. proteins

Abstract

A system and method for identifying and treating a disease in a patient collects one or more data streams from sensors configured to detect biological signals generated within a patient's tissue over time. Patient data elements including one or more of demographic, clinical, laboratory, pathology, chemical, image, historical, genetic, and activity data for the patient is collected and processed with the data streams to generate a personalized digital phenotype (PDP). The PDP is compared to a digital taxonomy comprising prior data to classify the patient into one or more quantitative disease classifications to guide personalized intervention for treating the patient.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/361 - Detecting fibrillation
• A61B 5/363 - Detecting tachycardia or bradycardia
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/08 - Measuring devices for evaluating the respiratory organs

Abstract

Methods are provided for the prevention and treatment of vascular inflammation. The methods comprise administering to a human subject an effective dose of an agent that specifically binds to CD47, and reduces one or more indicia of vascular inflammation.

IPC Classes  ?

• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Most nitrogen recovery techniques recover acidic ammonium fertilizers, and few enable alkaline ammonia recovery. Many embodiments provide multi-chamber electrochemical stripping reactors to recover alkaline ammonia and acidic ammonium from wastewater. The reactor combines electrodialysis and membrane stripping. The acidic and alkaline product portfolio for wastewater-derived ammonia expand implementation opportunities for nitrogen recovery.

IPC Classes  ?

• C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
• C02F 1/20 - Treatment of water, waste water, or sewage by degassing, i.e. liberation of dissolved gases
• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis

Abstract

Various methods and devices for treatment or assessment of structures or nerves accessible via the nasal cavity utilizing electrical stimulation or signal recording are provided. Devices can include one or more electrodes to provide electrical stimulation or signal recording. Electrodes can be disposed upon an inflatable balloon or a flat-surfaced tool or a precision tip.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

Processes and materials to detect cancer from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences derived from a neoplasm. Detection of somatic variants occurring in phase can indicate the presence of cancer in a diagnostic scan and a clinical intervention can be performed.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 30/10 - Sequence alignment; Homology search
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 35/20 - Screening of libraries
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
• G16H 70/60 - ICT specially adapted for the handling or processing of medical references relating to pathologies
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G16B 20/10 - Ploidy or copy number detection
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• C12Q 1/6869 - Methods for sequencing
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Abstract

Provided are modified microorganisms, such as live recombinant commensal bacteria, that express a non-native antigen, or are surface-labeled with a non-native antigen, and methods of using the modified microorganisms to induce an antigen-specific immune response to the non-native antigen. The modified microorganism can be used to induce a regulatory T cell immune response to the heterologous antigen to treat an autoimmune disease in a subject in need thereof, or can be used to induce an effector T cell immune response to the heterologous antigen to treat an infectious disease or proliferative disease in a subject in need thereof.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

Methods and compositions for the production of phospholipid-ligand bioconjugates and uniform targeted microbubbles are provided. These methods and compositions find use in ultrasound and molecular imaging applications related to cancer and other diseases. The methods of the present disclosure comprise contacting a phospholipid comprising a maleimide containing functional group with a ligand comprising a C terminal cysteine residue. The methods disclosed herein solves the problems in producing ready-to-use and clinically translatable ultrasound molecular imaging agents by incorporating small protein ligands engineered to bind against biomarkers representing pathological angiogenesis or abnormal cells. The methods also overcome the current limitations in producing uniformly targeted microbubbles in a scalable, economical and reproducible manner.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Systems and methods for the detection of musculoskeletal anomalies are disclosed. Various embodiments are directed to methods to detect and treat anomalies, including fracture (e.g. clavicle), deformity (e.g. scoliosis), and other anomalies. Various embodiments utilize structured white light scanners, while additional embodiments utilize LiDAR to generate 3-dimensional (3D) topographic scans. Various embodiments obtain these scans via a mobile device, such as a mobile phone or tablet. Further embodiments utilize machine learning models to analyze the 3D scans to identify an anomaly and/or a treatment for such anomaly and/or monitor change of that condition over time.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof
• G01S 17/89 - Lidar systems, specially adapted for specific applications for mapping or imaging
• G06T 15/08 - Volume rendering
• G06T 7/00 - Image analysis

Abstract

Survivors of central nervous system injury commonly present with spastic hypertonia. The affected muscles are hyperexcitable and can display involuntary static muscle tone and an exaggerated stretch reflex. These symptoms affect posture and disrupt activities of daily living. Symptoms are typically measured using subjective manual tests such as the Modified Ashworth Scale; however, more quantitative measures are necessary to evaluate potential treatments. The hands are one of the most common targets for intervention, but few investigators attempt to quantify symptoms of spastic hypertonia affecting the fingers. An Isometric Force Pillow (IFP) is provided herein to quantify involuntary grip force. This lightweight, computerized tool provides a holistic measure of finger flexion force and can be used in various orientations for clinical testing and to measure the impact of assistive devices.

IPC Classes  ?

• A61B 5/22 - Ergometry; Measuring muscular strength or the force of a muscular blow
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• A47G 9/10 - Pillows

Abstract

Antibiotic agents conjugated to a guanidinium-rich molecular transporter (GR-MoTr) are provided. The drug conjugates show surprising increases in efficacy compared to the unconjugated drug in difficult-to-treat bacterial infections including biofilms, stationary and persister cells, and multi-drug resistant bacteria, as well as intracellular bacteria.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 38/14 - Peptides containing saccharide radicals; Derivatives thereof
• A61P 31/04 - Antibacterial agents

Abstract

The present disclosure provides compositions, systems, and methods for genome editing, efficient knock-in of large DNA fragments, and long-term, stable, high expression of integrated transgenes. Also provided are modified cells, vaccines comprising modified cells, and methods of using such cells to induce an immune response.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 15/86 - Viral vectors
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• A61P 37/04 - Immunostimulants

Abstract

Provided herein are novel azopodophyllotoxin analog compounds, pharmaceutical compositions comprising them, and their use as inhibitors of Y box protein 1 (YB1 or YBX1) in treatments for conditions including gynecological, breast, bladder, kidney, head and neck, neuronal, and prostate cancers, lymphomas, and leukemias. Methods of their use in sensitizing resistant cancers to treatment with anticancer agents and radiation are also provided.

IPC Classes  ?

• A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• A61P 35/00 - Antineoplastic agents

Abstract

In certain examples, the present disclosure may involve use of filtering optics to provide a set of filter-separated light beams respectively associated with different polarization states of polarized light directed towards a sample, and providing a set of sample¬characterizing response data based on factors such as sets of polarization-state values, different wavelengths associated with the polarization states, and/or light-incidence angles characterizing separation of the different polarization states. More specific examples may include computing a Mueller matrix across an entire image, with the image being captured in a single shot in response to using filtering optics (e.g., metasurface polarization filtering to provide the set of filter-separated light beams). In another related example, sets of polarization-state values, corresponding Stokes vectors, may be used.

IPC Classes  ?

• G01N 21/21 - Polarisation-affecting properties
• G02B 27/28 - Optical systems or apparatus not provided for by any of the groups , for polarising